Oxford Biomedica Plc · LSE:OXB
Oxford Biomedica — Corporate Update (June 2018)
22 slides from Oxford Biomedica's corporate update, Jun 6, 2018
Slide 1: The LentiVector Platform Company: Oxford BioMedica and Axovant Licence Agreement
The LentiVector® Platform Company A leader in gene and cell therapy Oxford BioMedica and Axovant Worldwide Exclusive Licence Agreement for OXB-102 for Parkinson’s disease 06 June 2018
Slide 2: Forward-looking statements
Forward-looking statements This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed 2 Cohort
Slide 3: A world leading gene and cell therapy company
A world leading gene and cell therapy company Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34% Mean 29%
Slide 4: Strategy: Leveraging our delivery platform
Strategy: Leveraging our delivery platform LentiVector® Platform IP – patents and know-how | Facilities | Expertise | Quality systems Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Arising IP Max. up
Slide 5: Worldwide Exclusive Licence Agreement for OXB-102 (AXO-Lenti-PD)
Worldwide Exclusive Licence Agreement for OXB-102 (AXO-Lenti-PD)
Slide 6: Worldwide exclusive licence agreement with Axovant
Worldwide exclusive licence agreement with Licence agreement overview Key Terms Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1,• n=3Worldwide 1x exclusive licensing Original Mean 27%• agreement to Headline value $842.5 Mean 30% Mean million 29% Mean 20
Slide 7: Axovant: expertise and focus on neurological disorders
Axovant • Axovant Sciences (NASDAQ: AXON) is a US listed clinical-stage biopharmaceutical company dedicated to advancing treatments for patients Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) with life-altering neurologic conditions 1, n=3 1x Original Me
Slide 8: Products
x Oxford! Products
Slide 9: Product pipeline
Product pipeline Product Indication Pre-Clinical Phase I Phase I/II Phase II Phase III Approval Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) OXB Proprietary Products 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Corneal graft Max. up to 30% Ma
Slide 10: Parkinson's disease remains an area of high unmet medical need
Parkinson’s disease remains an area of high unmet medical need • Parkinson’s disease (PD) is a progressive neurodegenerative disorder resulting in the loss of Dose 2 Cohort dopamine in the striatum 3 months (UPDRS) Administration 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mea
Slide 11: AXO-Lenti-PD: a novel gene therapy for Parkinson's disease
AXO-Lenti-PD (formerly OXB-102): a novel gene therapy for Parkinson’s disease • AXO-Lenti-PD contains three genes that encode the critical enzymes required for dopamine synthesis Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • Tyrosine hydroxylase (TH):
Slide 12: AXO-Lenti-PD: designed to reduce motor fluctuations in Parkinson's disease
AXO-Lenti-PD (formerly OXB-102) : designed to reduce motor fluctuations in Parkinson’s disease Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% AXO-Lenti-PD* Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44
Slide 13: ProSavin (OXB-101) multiple doses evaluated in Phase I/II study
ProSavin®(OXB-101) multiple doses evaluated in Phase I/II study Mean Improvement in UPDRS-III (OFF) Score at 12 Months Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max
Slide 14: ProSavin sustained response observed several years after administration
ProSavin®(OXB-101) sustained response observed several years after administration Cohort2 Dose Administration 3 months (UPDRS) Mean UPDRS-III (OFF)6 months Score (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44%
Slide 15: AXO-Lenti-PD: a re-engineered gene therapy product
AXO-Lenti-PD (formerly OXB-102): a re-engineered gene therapy product AXO-Lenti-PD achieves up to 10-fold increases in dopamine + L-dopa production compared to ProSavin® (OXB-101), Cohort2 without impacting infusion volume or rate of administration Dose Administration 3 months (UPDRS) 6 months (UPDR
Slide 16: AXO-Lenti-PD increases catecholamine production compared to ProSavin
AXO-Lenti-PD (formerly OXB-102): increases catecholamine production compared to ProSavin® (OXB-101) Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up
Slide 17: Platform
x Oxford! Platform
Slide 18: Platform pipeline
Platform pipeline Product Cohort2 Indication Dose Pre-Clinical Administration Phase I 3 monthsPhase (UPDRS)I/II Phase 6 months II (UPDRS) Phase1 III Approval year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% LentiVector® platform Max. up to 30% Max. up to 50% Max. u
Slide 19: Summary
x Oxford! Summary
Slide 20: Expected news flow
Expected news flow Partners’ programmes Novartis Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 2nd CAR-T Royalty stream from Expected EMA approval for 1, n=3 1x Original 1 Mean 27% Mean 30% Mean 29% Mean 20% programme to Novartis/CTL019 paediatric r/r A
Slide 21: A world leading gene and cell therapy company
A world leading gene and cell therapy company Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34% Mean 29%
Slide 22: Contact Us
Contact Us Oxford BioMedica plc Windrush Court Transport Way Oxford OX4 6LT John Dawson, CEO Stuart Paynter, CFO Tel: +44 (0) 1865 783 000 [email protected] www.oxfordbiomedica.co.uk